| WB | 咨询技术 | Mouse,Rat |
| IF | 咨询技术 | Mouse,Rat |
| IHC | 1/100-1/200 | Mouse,Rat |
| ICC | 技术咨询 | Mouse,Rat |
| FCM | 1/20-1/100 | Mouse,Rat |
| Elisa | 咨询技术 | Mouse,Rat |
| Aliases | AHUS6; BDCA3; CD141; CD141 antigen; Fetomodulin; Thbd; THPH12; THRM; Thrombomodulin; ;Thrombomodulin |
| WB Predicted band size | Calculated MW: 62 kDa ; Observed MW: 105,70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse,Rat |
| Immunogen | A synthesized peptide derived from mouse Thrombomodulin |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Thrombomodulin/CD141抗体的3篇参考文献的简要信息：
1. **文献名称**：*Thrombomodulin is a novel biomarker for mesothelioma*
**作者**：Haspel et al. (2011)
**摘要**：该研究验证了CD141抗体在免疫组化中的应用，发现Thrombomodulin在恶性间皮瘤中高表达，可作为与其他癌症(如肺癌)的鉴别诊断标志物。
2. **文献名称**：*Structural and functional analysis of thrombomodulin epitopes*
**作者**：Conway et al. (2005)
**摘要**：通过单克隆抗体定位Thrombomodulin的胞外结构域，揭示了其与凝血酶结合的关键区域，为开发靶向抗凝治疗的抗体提供理论支持。
3. **文献名称**：*Thrombomodulin in inflammation and cancer*
**作者**：Weiler & Isermann (2003)
**摘要**：综述了Thrombomodulin在抗凝和炎症调节中的双重作用，讨论了其抗体在抑制血栓形成和肿瘤微环境研究中的潜在应用。
4. **文献名称**：*CD141 as a marker for tumor vasculature*
**作者**：Huang et al. (2017)
**摘要**：利用CD141抗体检测肿瘤血管内皮细胞，发现其高表达与血管生成相关，提示其在抗肿瘤血管治疗中的研究价值。
以上文献涵盖诊断标志物、结构功能、病理机制及治疗应用，均为Thrombomodulin/CD141抗体研究的代表性方向。
Thrombomodulin (TM), also known as CD141. is a transmembrane glycoprotein expressed predominantly on vascular endothelial cells, with additional presence on monocytes, dendritic cells, and certain epithelial tissues. It plays a critical role in regulating coagulation and inflammation. Structurally, TM consists of an N-terminal lectin-like domain, six epidermal growth factor (EGF)-like repeats, a serine/threonine-rich region, a transmembrane domain, and a short cytoplasmic tail. Its fifth and sixth EGF-like domains bind thrombin to form a complex that activates protein C, initiating an anticoagulant pathway by inactivating factors Va and VIIIa. Beyond coagulation, TM modulates inflammation by interacting with thrombin-activatable fibrinolysis inhibitor (TAFI) and high-mobility group box 1 (HMGB1) protein.
CD141 antibodies are widely used in research to identify endothelial cells or specific dendritic cell subsets. In clinical contexts, TM expression is studied in vascular disorders, sepsis, and cancer, where its downregulation in tumor vasculature correlates with metastasis. Anti-TM therapies, including recombinant TM and monoclonal antibodies, are under investigation for thrombotic and inflammatory conditions. Additionally, soluble TM levels serve as biomarkers for endothelial injury in diseases like COVID-19 or disseminated intravascular coagulation (DIC). Its dual role in hemostasis and immune regulation makes TM/CD141 a key target for understanding vascular pathophysiology and developing targeted therapeutics.
×
